
==== Front
ACS Omega
ACS Omega
ao
acsodf
ACS Omega
2470-1343 American Chemical Society 

10.1021/acsomega.9b04357
Article
Anticancer Effect of Rosiglitazone, a PPAR-γ
Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
Wu Yanqiao † Sreeharsha Nagaraja ‡ Sharma Sanjay § Mishra Anurag *∥ Singh Avinash Kumar ⊥ Gubbiyappa Shiva Kumar # † Intensive
Care Unit, People’s Hospital of Ningjin
County, Ningjin County, Shandong province 253400, China
‡ Department
of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia
§ NMIMS, School of Pharmacy and
Technology Management, Shirpur 425405, Maharashtra, India
∥ School
of Pharmacy, Suresh Gyan Vihar University, Jaipur 302017, Rajasthan, India
⊥ Department
of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
# School
of
Pharmacy, GITAM University, Hyderabad 530045, India
* E-mail: anuragmishra.sguv@gmail.com, anurag.mishra2@mygyanvihar.com.
04 03 2020 
17 03 2020 
5 10 5334 5339
18 12 2019 18 02 2020 Copyright © 2020 American Chemical Society2020American Chemical SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

Multiple effects
on cancer cells are exerted by the peroxisome
proliferator-activated receptor γ (PPAR-γ). Recent studies
have shown that rosiglitazone, a synthetic PPAR-γ ligand, inhibits
the growth of cells. This research was designed to assess the impact
of rosiglitazone on diethylnitrosamine (DENA)-induced lung carcinogenesis
in Wistar rats and to study the underlying molecular mechanism. A
total of 40 adult male Wistar rats were separated into four groups
as follows: group 1 is known as a control. Group 2 is known as the
DENA group (150 mg/kg, i.p.). Group 3 and group 4 denote DENA-induced
rats treated with 5 and 10 mg/kg rosiglitazone, respectively. Lipid
peroxidation, various antioxidant enzymes, histological perceptions,
and caspase-3, Bcl2, and Bax gene expression were measured in lung
tissues. Rosiglitazone treatment reverted the DENA-induced changes
in the expression of these genes, inflammatory cytokines, and oxidative
stress. However, blotting analysis discovered reduced caspase-3 and
BAX expressions and elevated Bcl-2 expression in DENA-induced rats.
The expression of such proteins causing DENA lung cancer was restored
by rosiglitazone therapy.

document-id-old-9ao9b04357document-id-new-14ao9b04357ccc-price
==== Body
Introduction
Lung cancer is the world’s leading
cause of cancer death.
Although numerous diagnosis and treatment strategies have been developed
for lung cancer, the overall five-year survival has not increased
considerably because of poor forecasts and lack of effective methods
for early detection. New treatment strategies for lung cancer, especially
molecular therapies, and the survival rate for patients with lung
cancer must be increased urgently. In addition, increased knowledge
of essential molecular modifications in normal cells leading to unstable
and malignant tumor cells may contribute to the development of possible
treatments for this disease. Lung cancer’s major risk factors
include air, aflatoxins, food additives, water, industrial toxic chemicals,
alcohol, and environmental pollutants. Diethylnitrosamine (DENA) is
known to be a lung cancer agent in smoke, cheddar cheese, cured meal,
drinking water, fried foods, pesticides, and cosmetics in the field
of agriculture and pharmaceuticals.1,2 DENA causes
lung cancer in laboratory animal models by inhibiting several enzymes
involved in the DNA repair process. In rats, DENA is a powerful pulmonary
carcinogen that affects the initiation of carcinogenesis during an
enhanced cell proliferation cycle with pulmonary necrosis. DENA-mediated
free radical production, increased lipid peroxidation (LPO), endogenous
antioxidant depletion, cytotoxicity, and carcinogenesis are recorded
in several studies.3,4

The nuclear hormone receptor
peroxisoma-activated receptor γ
(PPAR-γ) provides a strong link between lipid metabolism and
gene transcription regulation. A new class of antidiabetical medication
is now widely prescribed, and a group of PPAR-γ activators are
now commonly prescribed to control growth arrest and terminal differentiation
of adipocytes. Several ligands, such as rosiglitazone, pioglitazone,
troglitazone, and 15-deoxide-presaturated J2, have been identified,
and some polyunsaturated fatty acids are known. In several organ groups,
PPAR-α is expressed: intestines, adipose, pulmonary tissue,
breasts, and liver. Several studies have shown that PPAR-β ligand
cancer cells can induce cell differentiation and apoptosis and have
proposed potential uses as chemopreventive carcinogenesis agents.5,6 This together led us to start these research studies to gain insights
into the possibility of rosiglitazone supplement safety based on the
mechanism against DENA-induced lung cancer.

Results and Discussion
Effect
of Rosiglitazone on LPO and Antioxidant Enzymes
Determining
thiobarbituric acid reactive substances was used to determine
LPO in the fresh lung homogenate. In the group DENA, the amount of
malondialdehyde (MDA) (an LPO marker) increased 341.1% but was lower
at 27.4 and 71.8% following the 5 and 10 mg/kg supplementation of
rosiglitazone, respectively (Figure 1A). In the DENA group, reduced glutathione (GSH) levels
(an antioxidant marker) decreased by 71.3% but increased by 76.9 and
193.8% after 5 and 10 mg/kg supplementation of rosiglitazone, respectively.
The activity of another antioxidant marker, Gpx, decreased in the
DENA group by 63.2%. However, after 5 and 10 mg/kg of rosiglitazone
supplementation, the activities of Gpx increased by 69.3 and 184.5%,
respectively. The activity of the additional antioxidant marker superoxide
dismutase (SOD) in the DENA group was reduced by 61.3% and increased
by 27.4% and 104.2%, respectively, after 5 and 10 mg/kg of rosiglitazone
supplementation. Catalase (CAT) activity, the marker for antioxidants,
decreased in DENA groups by 73.5% but increased by 84.3 and 193.2%,
respectively, as a consequence of 5 and 10 mg/kg rosiglitazone supplementation
(Figure 1B).

Figure 1 Effects of
rosiglitazone on LPO and antioxidant enzymes. (A) MDA
levels; (B) GSH, SOD, CAT, and GPx levels. Analysis and evaluation
of experimental data were performed using ANOVA, followed by the Tukey
post hoc test for group average comparisons. ###P < 0.001 in contrast with the control group; *P < 0.05, **P < 0.01, and ***P < 0.001 in contrast with the DENA group. Findings were
shown as means and SD (n = 10).

The most common human cancer in the world is pulmonary cancer.
Because the human race around the world is at serious health risk
and existing chemical therapies have serious adverse impacts, numerous
research programs are focused on discovering novel therapeutic agents.
Apoptosis has been considered an effective therapeutic goal because
deregulated apoptosis contributes to carcinogenesis. The anticancer
impact of rosiglitazone against lung cancer induced by DENA in experimental
animals is explained in the present study. Reactive oxygen species
(ROS) play a major role in lung cancer caused by DENA.7,8 Initiating, promoting, and progressing lung cancer through oxidation,
ROS, and LPO play an important role. Oxidative stress is due to an
imbalance between ROS manufacture and cellular antioxidant defense
detoxification of reactive intermediates. The increase in LPO in carcinogenesis
can result in a high level of carcinogenic MDA, which is an LPO product.
Several investigators reported significantly reduced activities of
SOD, CAT, GPx, GST and GSH in cancer-bearing animals with elevated
free radicals and various humoral and cellular mediators. Multiple
researchers have recorded substantially lower GST, CAT, GSH, Gpx,
and SOD activity in carcinogenic animals with high free radicals and
certain humoral factors.9,10 Lower respiratory tract
glutathione and related enzymes can be the first line of defense for
lung injury in the epithelial body.11,12

Effect of Rosiglitazone
on Inflammatory Cytokines
In
the DENA group, the TNF-α rate was increased by 284.7% but reduced
by 31.6 and 106.3% after 5 and 10 mg/kg of rosiglitazone supplementation,
respectively (Figure 2A). The DENA group showed an increase in IL-1β by 327.8%, but
reduced by 28.4 and 94.8% following 5 and 10 mg/kg of rosiglitazone
supplementation (Figure 2B). Like IL-6, IL-1β and TNF-α levels were also amplified
by 197.8% in the DENA group but decreased, respectively, by 27.6%
and 74.0% from 5 to 10 mg/kg rosiglitazone supplementation (Figure 2C).

Figure 2 Effects of rosiglitazone
on TNF-α, IL-1β, and IL-6
levels (pg/mL) in DENA-induced rats. (A) TNF-α levels; (B) IL-1β
levels; and (C) IL-6 levels. Analysis and evaluation of experimental
data were performed using ANOVA, followed by the Tukey post hoc test
for group average comparisons. ###P <
0.001 in contrast with the control group; *P <
0.05, **P < 0.01, and ***P <
0.001 in contrast with the DENA group. Findings were shown as means
and SD (n = 10).

Cytokines have important roles in host defense and pathophysiology
under inflammatory conditions. After administration of DENA in rats,
the development of IL-6, IL-1β, and TNF-α has increased
suggestively in this investigation.13−15 Western blot analysis
has shown that the administration of DENA significantly increased
pro-apoptotic Bax protein expression and decreased Bcl-2 expression.
Cytochrome c has been released into the mitochondrial
cytosol, and then, caspase-3 expression was increased.16,17 This causes apoptosis of the tumor cells. Both effects can enhance
the chemical therapy effect in combination with rosiglitazone (5 and
10 mg/kg) and reduce DENA’s toxicity, depending on the dosage.

Effect of Rosiglitazone on mRNA Expression of Caspase-3, Bax,
and Bcl-2
The downstream caspase function in both the nucleus
and the targets for the cytosol is caspase-3, a central executor of
apoptosis in programmed cell death. To test the hypothesis of a lower
level of Caspase-3 in rat because of rosiglitazone, quantitative real-time
polymerase chain reaction (qRT-PCR) and western blotting analysis
were performed on the mRNA and Caspase-3 protein expressions. In comparison
with the control group, as shown in Figure 3A–C, the caspase-3 mRNA and protein
levels were considerably higher in the DENA-driven rats, while the
dose-dependent treatment was substantially reversed by rosiglitazone
(5 and 10 mg/kg). Accumulating studies have shown that the increase
of proapoptotic protein Bax and decrease of antiapoptotic protein
Bcl-2 promoted cytochrome c release in mitochondria, and therefore
activated the cascades of apoptosis.

Figure 3 Effects of rosiglitazone on mRNA expression
and protein levels
of caspase-3, Bax, and Bcl-2. (A) Relative expression of caspase-3,
Bax, and Bcl-2 measured by qRT-PCR. (B–E) Protein expressions
of Bcl-2, caspase-3, and Bax were measured by western blotting. β-Actin
was used as an internal standard. Analysis and evaluation of experimental
data were performed using ANOVA, followed by the Tukey post hoc test
for group average comparisons. ###P <
0.001 in contrast with the control group; *P <
0.05, **P < 0.01, and ***P <
0.001 in contrast with the DENA group. Findings were shown as means
and SD (n = 10).

Western blot analysis demonstrated that DENA administration substantially
increased the expression of the pro-apoptotic protein Bax and diminished
the expression of the anti-apoptotic protein Bcl-2. Cytochrome c has been released into the cytosol from the mitochondria,
which increases caspase-3 protein expression.16,17 It induces apoptosis of the tumor cells. These effects can improve
the chemotherapy effect and lower the dose-dependent toxicity of DENA
in combination with rosiglitazone (5 and 10 mg/kg).

Effects of
Rosiglitazone on DENA-Mediated Lung Histopathological
Changes
The lungs were isolated at 24 h after administration
of rosiglitazone in the lung tissue to assess histological changes
following rosiglitazone post treatment in DENA-challenged rats. The
control group’s lung tissues had a normal structure, and there
were no histopathological changes. Histological examination of the
DENA group by hematoxylin and eosin (H&E) staining revealed serious
pulmonary oedema, stroma hemorrhagia, alveolar collapse, and mass
inflammatory cell infiltrations, which were seriously destructive
of the lung. Nonetheless, after treatment with rosiglitazone (5 and
10 mg/kg), effective alleviation of lung structure degradation was
observed, depending on the dosage (Figure 4).

Figure 4 Histopathological images of the effect of rosiglitazone
on DENA-induced
carcinogenensis in lung tissues of Wistar rats (H&E; 200×).

Conclusions
In brief, the results
of this study showed that rosiglitazone can
reduce lung carcinogenesis induced by DENA by downregulating LPO,
inflammatory cytokines such as IL-6, IL-1β, and TNF-α,
and pro-apoptotic factors Bax, whereas upregulating antioxidant enzyme
levels such as SOD, CAT, Gpx, GST, and GSH and the anti-apoptotic
factor Bcl-2. Further clinical study is required to find out an exact
effect.

Materials and Methods
Chemicals
DENA and rosiglitazone
have been acquired
from Sigma-Aldrich. The cell signaling technique was used to acquire
both primary and HRP-conjugated secondary antibodies. The western
blotting kit has been obtained from Abcam, USA. All other chemicals
used were of analytical quality.

Experimental Animals
This study was conducted on male
Wistar rats (220 ± 10 g). All the animals were procured from
and maintained in the central animal house of People’s Hospital
of Ningjin County, China. Animals were caged in groups with the normal
12 h light/dark cycle maintained at 24 ± 2 °C temperature.
The animals were served pelleted rat chow and water ad libitum, available
commercially. All animal procedures were approved by the animal ethical
committee of People’s Hospital of Ningjin County (AECPN NO:
AECP/11827/2019). The experiment was carried out according to the
guidelines of the NIH at the People’s Hospital of Ningjin County.

Experimental Design
As described earlier, the DENA-induced
animal model of lung cancer has been developed. The animals were intraperitoneally
(i.p.) given 150 mg/kg body weight dosage of DENA for 21 days once
in 7 days. The rats have been split into four different categories,
comprising 10 rodents per group, randomly following the induction
of lung cancer: Group 1 was treated as a normal control and only distillated
water not exceeding 1 mL was given orally. Group 2 was i.p. given
150 mg/kg DENA. In groups 3 and 4, rats were treated with DENA orally
for 15 days with 5 and 10 mg/kg rosiglitazone, respectively. Feed
was deprived overnight for 24 h after the last operation, and all
rats were anesthetized. Jugular vein blood was obtained and serum
was isolated and used for the biochemical investigation. For histopathological
analysis, 10% of the tissue was seeded in formaldehyde. The remaining
tissue weighed and about 100 mg of tissue was homogenized with chilled
0.1 M Tris-HCl buffer for biochemical analysis in a homogenizer. For
further examination, the lung tissue was stored at −80 °C.18

Measurement of LPO and Antioxidant Enzymes
LPO was
measured in fresh pulmonary homogenates according to Quintero-García
et al. by the detection of thiobarbituric acid reactants. The final
product of LPO has been determined by measuring the absorption at
534 nm. A measurement of the absorption of CAT activity at 420 nm
was performed. The specimens were supplied with 500 μL of phosphate
buffer, serum, and liquid. The absorption was estimated at 560 nm
for SOD. A specimen with phosphate (1.2 mL), homogeneous tissue (0.1
mL), nitroblue tetrazolium (0.3 mL), and NADH (0.2 mL) was used. Following
the procedure of the GSH content was determined by the Ellman reaction
in the lung tissue homogenates. At 412 nm, the final product was measured.
The absorption was measured at 340 nm to determine the activity of
Gpx in the tissue homogenate.19

Measurement
of Inflammatory Cytokines
IL-6, IL-1β,
and TNF-α levels in serum were measured using rat cytokine (Xitang
Biotechnology Co., Ltd., Shanghai, China) kits, which are commercially
available immunosorbent assays [enzyme-linked immunosorbent assay
(ELISA)]. The experiments with ELISA were performed following strict
directions.20

Quantitative Real-Time
Polymerase Chain Reaction
A
total DNA protein kit (E.Z.N.A.) was utilized for total lung RNA extraction.
A BCA protein assay kit has been used to assess protein concentrations.
Total RNA (1 μg) was reverse-transcribed with an ImProm-II reverse
transcription system package. For mRNA amplification of apoptosis-related
genes using the following front and reverse primers (Table 1), an ABI PRISM 7500 sequence
detection system was applied. The conditions for amplification are
30 s at 95 °C and then 39 cycles of 5 s at 95 °C, 30 s at
58 °C, and 34 s at 72 °C. Caspase-3, Bax, and Bcl-2 levels
of mRNA are standardized to β-actin levels. Triplicate studies
have been performed. All data were examined with the 2–ΔΔCt process (ΔCt = CtTarget gene – Ctβ-actin, ΔΔCt = ΔCt exp –
ΔCtControl).21

Table 1 Primer Sequence for RT-PCR
name	sequence (5′ → 3′)	
Caspase-3	forward primer: CGGAGCTTGGAACGCGAAG	
 	reverse primer: ACACAAGCCCATTTCAGGGT	
Bax	forward primer: ACAACAGCAGCACAACAGCC	
 	reverse primer: GTGTAAACCGCAGCCGAAGG	
Bcl-2	forward primer: GATTCCCTCTCCCCACTGCC	
 	reverse primer: TGCTTTCTTTTTCGCCGCGT	
β-actin	forward primer:
CCCAGCCATGTACGTAGCCA	
 	reverse primer: CCGTCTCCGGAGTCCATCAC	
Histopathological Study
The method
by Fukushi et al.
has been used in histopathological study of the lung tissue. The lower
lobe of the lung was soaked in 10% formalin and immersed in paraffin.
Tissues are cut to 3 μm thickness and treated with H&E.
A tissue section under a light microscope was then examined. Sections
are tested under a light microscope at a magnification of 100×.22

Western Blotting
Equal amounts of
the total protein
are filled in 80 V sodium dodecyl sulfate–polyacrylamide gel
electrophoresis gels for 80 min, electrically transferred to polyvinylidene
fluoride membranes by the wet transfer method (250 mA, 90 min), and
blocked in 5% bovine serum albumin at 4 °C overnight. Subsequently,
the membranes were incubated with an anti-β- actin antibody
(dilution 1:1000), anticaspase3 antibody (dilution 1:200), anti-bcl-2
antibody (dilution 1:100), and anti-bax antibody (dilution 1:500)
at room temperature for 2 h. After TBST washing, membranes were incubated
for 1 h at room temperature with secondary goat anti-mouse IgG (dilution
1:1000) and were combined with horseradish peroxidase. Equal protein
loads were verified with anti-β-actin antibody on each lane.
The reagent chemiluminescence was then observed with proteins. Bio-Rad
Quantity One v4.62 was used to calculate the density of the protein
band. Protein expression levels were normalized internally with β-actin.23

Statistical Analysis
All test data
are shown as standard
deviation (SD) and means. Experimental results are analyzed and compared
by means of analysis of variance (ANOVA), followed by the post hoc
Tukey test, which showed P < 0.05, suggesting
statistical significance for group mean comparisons. SPSS for Windows,
version 22, has been used for all statistical analysis.

The authors declare no
competing financial interest.

Acknowledgments
Authors would like to thank People’s
Hospital
of Ningjin County, China, for providing a laboratory facility and
all chemicals.

Abbreviations
BaxBcl2-associated X protein

Bcl2B-cell lymphoma 2

CATcatalase

DENAdiethylnitrosamine

ELISAenzyme-linked
immunosorbent assay

Gpxglutathione peroxidase

IL-1βinterleukin 1 beta

IL-6interleukin-6

GSHreduced glutathione

MDAmalondialdehyde

PPAR-γperoxisome proliferator-activated receptor γ

qRT-PCRquantitative real-time
polymerase chain reaction

ROSreactive oxygen species

SDstandard deviation

SODsuperoxide dismutase

TNF-αtumor necrosis factor-alpha
==== Refs
References
Akagi K. ; Hirose M. ; Hoshiya T. ; Mizoguchi Y. ; Ito N. ; Shirai T. 
Modulating effects
of ellagic acid, vanillin and quercetin
in a rat medium term multi-organ carcinogenesis model
. Cancer Lett. 
1995 , 94 , 113 –121
. 10.1016/0304-3835(95)03833-i .7621439 
Armstrong D. ; Cameron R. G. 
Comparison of liver
cancer and nodules induced in rats
by deoxycholic acid diet with or without prior initiation
. Cancer Lett. 
1991 , 57 , 153 –157
. 10.1016/0304-3835(91)90209-z .1673872 
Balansky R. ; Novikov L. ; Giannoni P. ; Izzotti A. ; De Flora S. 
No effect
of treatment with carcinogens on cytosine methylation of mitochondrial
DNA isolated from rat organs by phenol-free alkaline extraction
. Cancer Lett. 
1995 , 97 , 17 –23
. 10.1016/0304-3835(95)03943-q .7585473 
Béréziat J.-C. ; Raffalli F. ; Schmezer P. ; Frei E. ; Geneste O. ; Lang M. A. 
Cytochrome
P450 2A of nasal epithelium: regulation
and role in carcinogen metabolism
. Mol. Carcinog. 
1995 , 14 , 130 –139
. 10.1002/mc.2940140209 .7576100 
Ceriello A. ; Mezza F. ; Cozzolino S. ; Pettinato G. ; Mancini A. ; Santaniello W. ; Calise F. ; Cuomo O. 
Role of immunosuppression
in recurrence after liver transplantation for diethylnitrosamine-induced
tumors in rats
. Transplant Int. 
1994 , 7 , 204 –207
. 10.1111/j.1432-2277.1994.tb01347.x .
Cortinovis C. ; Klimek F. ; Nogueira E. 
Rat hepatocarcinogenesis
induced
by N-nitrosodiethylamine and N-nitrosomorpholine continuously administered
at low doses. From basophilic areas of hepatocytes to hepatocellular
tumors
. Am. J. Pathol. 
1991 , 139 , 1157 –1171
.1951631 
Cui Y. ; Zha Y. ; Li T. ; Bai J. ; Tang L. ; Deng J. ; He R. ; Dong F. ; Zhang Q. 
Oxidative
effects of lungs in Wistar
rats caused by long-term exposure to four kinds of China representative
chrysotile
. Environ. Sci. Pollut. Res. Int. 
2019 , 26 , 18708 –18718
. 10.1007/s11356-019-04978-6 .31055741 
Gramatté J. ; Pietzsch J. ; Bergmann R. ; Richter T. 
Causative treatment
of acid aspiration induced acute lung injury - Recent trends from
animal experiments and critical perspective
. Clin. Hemorheol. Microcirc. 
2018 , 69 , 187 –195
. 10.3233/ch-189113 .29630538 
Liu X. ; Liu J. ; Liu D. ; Han Y. ; Xu H. ; Liu L. ; Leng X. ; Kong D. 
A cell-penetrating
peptide-assisted
nanovaccine promotes antigen cross-presentation and anti-tumor immune
response
. Biomater. Sci. 
2019 , 7 , 5516 10.1039/c9bm01183h .31670734 
Imam F. ; Al-Harbi N. O. ; Al-Harbi M. M. ; Qamar W. ; Aljerian K. ; Belali O. M. ; Alsanea S. ; Alanazi A. Z. ; Alhazzani K. 
Apremilast
ameliorates carfilzomib-induced pulmonary inflammation and vascular
injuries
. Int. Immunopharmacol. 
2019 , 66 , 260 –266
. 10.1016/j.intimp.2018.11.023 .30500623 
Jiang Y. ; You F. ; Zhu J. ; Zheng C. ; Yan R. ; Zeng J. 
Cryptotanshinone
Ameliorates Radiation-Induced Lung Injury in Rats
. J. Evidence-Based Complementary Altern. Med. 
2019 , 2019 , 1908416 10.1155/2019/1908416 .
Akl M. A. ; Kartal-Hodzic A. ; Suutari T. ; Oksanen T. ; Montagner I. M. ; Rosato A. ; Ismael H. R. ; Afouna M. I. ; Caliceti P. ; Yliperttula M. ; Samy A. M. ; Mastrotto F. ; Salmaso S. ; Viitala T. 
Real-Time Label-Free Targeting Assessment
and in Vitro Characterization of Curcumin-Loaded Poly-lactic-co-glycolic
Acid Nanoparticles for Oral Colon Targeting
. ACS Omega 
2019 , 4 , 16878 –16890
. 10.1021/acsomega.9b02086 .31646234 
Yang Y. ; Huang Z. ; Li J. ; Mo Z. ; Huang Y. ; Ma C. ; Wang W. ; Pan X. ; Wu C. 
PLGA Porous Microspheres
Dry Powders for Codelivery of Afatinib-Loaded Solid Lipid Nanoparticles
and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors
Resistant Nonsmall Cell Lung Cancer
. Adv. Healthcare
Mater. 
2019 , 8 , 1900965 10.1002/adhm.201900965 .
Lin X. ; Ju Y.-n. ; Gao W. ; Li D.-m. ; Guo C.-c. 
Desflurane
Attenuates Ventilator-Induced Lung Injury in Rats with Acute Respiratory
Distress Syndrome
. BioMed Res. Int. 
2018 , 2018 , 7507314 10.1155/2018/7507314 .29670906 
Liu W. ; Liu K. ; Zhang S. ; Shan L. ; Tang J. 
Tetramethylpyrazine
Showed Therapeutic Effects on Sepsis-Induced Acute Lung Injury in
Rats by Inhibiting Endoplasmic Reticulum Stress Protein Kinase RNA-Like
Endoplasmic Reticulum Kinase (PERK) Signaling-Induced Apoptosis of
Pulmonary Microvascular Endothelial Cells
. Med.
Sci. Monit. 
2018 , 24 , 1225 –1231
. 10.12659/msm.908616 .29488473 
Miri S. ; Rasooli A. ; Brar S. K. 
Data on
changes of NF-kappaB gene
expression in liver and lungs as a biomarker and hepatic injury in
CLP-induced septic rats
. Data in brief 
2019 , 25 , 104117 10.1016/j.dib.2019.104117 .31428666 
Najafi M. ; Shirazi A. ; Motevaseli E. ; Geraily G. ; Amini P. ; Shabeeb D. ; Eleojo Musa A. 
Evaluating
the Expression of NOX2
and NOX4 Signaling Pathways in Rats’ Lung Tissues Following
Local Chest Irradiation; Modulatory Effect of Melatonin
. Int. J. Mol. Cell. Med. 
2018 , 7 , 220 –225
. 10.22088/IJMCM.BUMS.7.4.220 .31516881 
Becker R. A. ; Shank R. C. 
Kinetics of formation
and persistence of ethylguanines
in DNA of rats and hamsters treated with diethylnitrosamine
. Cancer Res. 
1985 , 45 , 2076 –2084
.3986763 
Quintero-García M. ; Delgado-González E. ; Sánchez-Tusie A. ; Vázquez M. ; Aceves C. ; Anguiano B. 
Iodine prevents the
increase of testosterone-induced oxidative stress in a model of rat
prostatic hyperplasia
. Free Radical Biol. Med. 
2018 , 115 , 298 –308
. 10.1016/j.freeradbiomed.2017.12.014 .29248723 
Mazzio E. A. ; Bauer D. ; Mendonca P. ; Taka E. ; Soliman K. F. A. 
Natural
product HTP screening for attenuation of cytokine-induced neutrophil
chemo attractants (CINCs) and NO2- in LPS/IFNgamma activated glioma
cells
. J. Neuroimmunol. 
2017 , 302 , 10 –19
. 10.1016/j.jneuroim.2016.11.012 .27956075 
Liu H. ; Xu H. ; Ma H. ; Luo L. ; Yang L. ; Chen F. ; Qu X. ; Liu H. ; Zhang R. 
LncRNA CASC2 inhibits astrocytic
activation and adenosine metabolism by regulating PTEN in pentylenetetrazol-induced
epilepsy model
. J. Chem. Neuroanat. 
2020 , 101749 10.1016/j.jchemneu.2020.101749 .31958564 
Wang L. ; Zhou Y. ; Wang X. ; Zhang G. ; Guo B. ; Hou X. ; Ran J. ; Zhang Q. ; Li C. ; Zhao X. ; Geng Y. ; Feng S. 
Mechanism of Asbt (Slc10a2)-Related
Bile Acid Malabsorption in Diarrhea after Pelvic Radiation
. Int. J. Radiat. Biol. 
2020 , 1 –10
. 10.1080/09553002.2020.1707324 .
Low L. D. ; Lu L. ; Chan C. Y. ; Chen J. ; Yang H. H. ; Yu H. ; Lee C. G. L. ; Ng K. H. ; Yap H. K. 
IL-13-driven alterations
in hepatic cholesterol handling contributes to hypercholesterolemia
in a rat model of minimal change disease
. Clin.
Sci. 
2020 , 134 , 225 10.1042/CS20190961 .31934720

